HER2 Expression Informs Eligibility for ENHERTU® in 2L HER2+ mBC Discussion – April 9th
On behalf of Daiichi Sankyo, Inc. and AstraZeneca, we cordially invite you to join us for an informative, expert-led discussion exploring the clinical significance of HER2 expression in eligible patients with mBC. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic: HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either 1) in the metastatic setting, or 2) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
Learning Objectives:
- Examine the unmet need for patients with HER2+ mBC
- Review the clinical efficacy and safety data of an ENHERTU clinical trial in HER2+ mBC
- Learn about dosage and administration of ENHERTU
Date: Apr 9th, 2025, 6:30 PM – 8:00 PM, Pacific Standard Time
Faculty: Nitin Rohatgi, MD, Sutter Cancer Center, Sacramento
Location: Be Steak A, 1887 South Bascom Avenue, Campbell, CA 95008
RSVP: Joyce Lew, (415) 987-8862 or By: 4/1/2025